Department of Medicine

Division of Endocrinology

/med/depts/

Additional Information

Contact Us

Health Science Campus
Ruppert Health Center
Room # 0012
Phone: 419.383.3685
Fax: 419.383.6244 webmaster@utoledo.edu

Endocrinology, Diabetes and Metabolism Research

2016 RESEARCH SUMMARY

Our group also conducts clinical/translational research at outpatient clinics and inpatient service sites within the University of Toledo Health Campus (UT Medical Center, Ruppert Health Center, Dana Cancer Center) and the ProMedica Health Campus (The Toledo Hospital and the Falzone Diabetes Center). 

Scientifically, the Division’s research encompasses clinical, translational and basic science areas as described below:

 Current Clinical/Translational projects include:

  1. Latent Autoimmune Diabetes of Adult Database Study
  2. Anti-Program Cell Death-1 Pathway Blockade and Type 1 Diabetes Development (NEW MEDTRONIC GRANT AWARD)
  3. Calcitonin Enhanced Localization of Parathyroid Adenomas
  4. Thyroid Nodule Database Study
  5. Insulin Antibodies and Insulin Resistance
  6. New Onset Diabetes After Transplant (NODAT)

Current Basic/Translational projects include:

  1. Characterization of a New Humanized Transgenic Model of Type 1 Diabetes
  2. Experimental Immunotherapeutic Approaches for Treatment of Type 1 Diabetes
  3. Thyroid Cancer Biomarkers
  4. Tumor Immunity Studies

The Division’s basic research program is conducted at the:

Center for Diabetes and Endocrine Research (CeDER)

Recent/relevant peer reviewed abstracts/papers

  1. M.R. Haymart, D. Repplinger, J.C. Jaume and H. Chen.  What’s in a number? The role of TSH in predicting thyroid cancer. American Thyroid Association.  New York, New York 2007
  2. M.R. Haymart, D.J. Repplinger, G.E. Leverson, D.F. Elson, R.S. Sippel, J.C. Jaume, H. Chen.  Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J. Clin. Endocrinol. Metab. 2008 Mar;93(3):809-14. Epub 2007 Dec 26, 2007.
  3. S. Mirocha, S. Salamat and J.C. Jaume.  Lymphogranulomatous hypophysitis, an intermediate state on the natural evolution of the disease or a new entity?  The Endocrine Society.  Toronto, Canada 2007.
  4. R.B. Elagin, S.Y. Balijepalli, M.J. Diacovo, S. Baekkeskov and J.C. Jaume*.  Antigen specific insulitis in “humanized” transgenic mice. The Endocrine Society.  Toronto, Canada 2007. (*oral communication in new BENCH TO BEDSIDE session).
  5. S. Mirocha, R. B. Elagin, S. Salamat and J.C. Jaume.  T regulatory cells distinguish two types of primary hypophysitis.  Clin. Exp. Immunol.  2008 Mar;155(3):403-11. Epub 2008 Dec 5.
  6. M.R. Haymart, S.L. Glinberg, J. Liu, R.S. Sippel, J.C. Jaume and H. Chen. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf).  2009 Sep;71(3):434-9.
  7. R.B. Elagin and J.C. Jaume*.  Glucose intolerance from antigen specific insulitis in “humanized” transgenic mice.  The Endocrine Society.  San Francisco, California 2008. (*oral communication in new BENCH TO BEDSIDE session).
  8. M.R. Haymart, S.L. Glinberg, J. Liu, R.S. Sippel, J.C. Jaume and H. Chen.  Is the association of cancer and higher TSH a matter of age? American Thyroid Association.  Chicago, Illinois 2008
  9. R.B. Elagin, S.Y. Balijepalli, M.J. Diacovo, S. Baekkeskov and J.C. Jaume.  Homing of GAD65 specific autoimmunity and development of insulitis requires expressing of both DQ8 and human GAD65 in transgenic mice.   J. Autoimmun.  2009 Aug;33(1):50-7.  Epub 2009 Mar 16.
  10. A. Staii and J.C. Jaume.  Unexpected High Prevalence of Hashimoto’s Thyroiditis Diagnosed by Ultrasound-Guided FNA.  The Endocrine Society.  Washington, DC 2009.
  11. R.B. Elagin and J.C. Jaume*.  Type 1 Diabetes Antigen-Specific “Humanized” Transgenic Model. Evidence for Regulatory T cell Controlled Insulitis.  The Endocrine Society.  Washington, DC 2009. (*oral communication in new BENCH TO BEDSIDE session)
  12. K. Todorova-Koteva and J.C.Jaume.  Subcutaneous recombinant human parathyroid hormone (PTH) injection provides a diagnostic tool for identification of non-phenotypically evident pseudohypoparathyroidism by unmasking PTH resistance.  Endo Trends. 2010 Feb;4(16):9-11.
  13. R.B. Elagin and J.C. Jaume.  Glucose intolerance and diabetes following antigen-specific insulitis in diabetes-susceptible "humanized" transgenic mice.  Biochem Biophys Res Commun. 2010 Apr 23;395(1):99-103.
  14. K. Todorova-Koteva, A. Staii and J. C. Jaume*.  Non-Clinical (Euthyroid) Hashimoto Thyroiditis as a Risk Factor for Thyroid Cancer.  The Endocrine Society.  San Diego, CA 2010.  *Presidential Award Winner.
  15. S. Sirinvaravong, S. Imam and J. C. Jaume.  Simultaneous Medullary and Papillary Thyroid Cancer.  Cancer Stem Cell Prototype or Coexistence?  American Thyroid Association.  Palm Springs, CA 2011.
  16. A. Staii, S. Mirocha, K. Todorova-Koteva, S. Glinberg and J.C. Jaume.  Hashimoto thyroiditis is more frequent than expected when diagnosed by cytology which uncovers a pre-clinical state.  Thyroid Research 2010 Dec 20;3(1):11.
  17. J.C. Jaume and H. Chen.  Inadequate Cytology of Thyroid Nodules.  Repeat it or live with it. Ann Surg Oncol 2011; 18:1222–1223.
  18. R. Paparodis, K. Naraharisetty, and J. C. Jaume.  Does thyroid function in Hashimoto’s influence thyroid cancer development?  The Endocrine Society.  Houston, TX 2012.
  19. K. Todorova-Koteva, K. Wood, S. Imam and J.C. Jaume.  Screening for parathyroid hormone resistance in non-phenotypically evident pseudohypoparathyroidism. Endocr Pract 2012; 11:1-21.
  20. S. Imam, R.B. Elagin and J.C. Jaume.  Diabetes-Associated Dry Eye Syndrome in a New Humanized Transgenic Model of Type 1 Diabetes.  Mol Vis 2013;19:1259-67.
  21. S. Imam, R. G. Mirmira and J. C. Jaume.  EIF5A Inhibition Alters Immune Responses in a “Humanized” Transgenic Mouse Model of Type 1 Diabetes.  American Diabetes Association.  Chicago, IL 2013.
  22. S. Imam, and J. C. Jaume.  Thyroid cancer immunoediting by regulatory double negative (DN) T cells. American Association of Cancer Research. Washington, DC 2013. (Late Breaking Abstract)
  23. N. Chongkrairatanakul, H. Chen and J. C. Jaume.  Risk of Thyroid Cancer in Follicular Lesion of Undetermined Significance Differs Significantly Among Academic Institutions: Should Management Be Tailored to Local Experience?  The Endocrine Society.  San Francisco, CA 2013.
  24. R. Paparodis and J. C. Jaume. Functional Hashimoto Thyroiditis is Associated with Increased Risk for Thyroid Cancer.  The Endocrine Society.  San Francisco, CA 2013.
  25. R. Paparodis and J. C. Jaume. High Titers of Thyroid Peroxidase Antibodies appear Protective for Thyroid Cancer in Patients with Hashimoto Thyroiditis.  The Endocrine Society.  San Francisco, CA 2013.
  26. N. Coorough, K. Hudak, J.C. Jaume, D. Buehler, S. Selvaggi, J. Rivas, R. Sippel, H. Chen.  Non-Diagnostic Fine Needle Aspirations of the Thyroid:  Is the Risk of Malignancy Higher?  J Surg Res 2013;184:746-50
  27. R. Paparodis and J. C. Jaume. Repeat FNA Biopsies for Thyroid Nodules: Risk Factors for Differentiated Thyroid Cancer.  The Endocrine Society.  San Francisco, CA 2013.
  28. S. Pandey, V. L.  Cryns and J. C. Jaume.  Decade of Hashimoto thyroiditis Followed by Graves disease.  The Endocrine Society.  San Francisco, CA 2013.
  29. S. Thida S. Imam, R. McKenney and J. C. Jaume.  Does Interferon Beta 1a (IFNβ 1a) Treatment for Multiple Sclerosis Alter the Immune Microenvironment of Papillary Thyroid Cancer (PTC)?  American Thyroid Association.  San Juan de Puerto Rico, PR 2013.
  30. R. McKenney and J. C. Jaume.  Extramedullary Plasmacytoma of the Thyroid Diagnosed with Ultrasound-Guided Core Needle Biopsy.  American Thyroid Association.  San Juan de Puerto Rico, PR 2013.
  31. S. Imam, R.G. Mirmira and J.C. Jaume.  Eukaryotic translation initiation factor 5A inhibition alters immune responses in a “humanized” transgenic mouse model of type 1 diabetes.  Am J Physiol Endocrinol Metab. 2014;306:E791-8
  32. R. Paparodis and J. C. Jaume.  High Titers of Thyroid Peroxidase, Thyroglobulin and TSH-Receptor Antibodies Appear Protective for Thyroid Cancer in Patients with Graves Disease.  The Endocrine Society.  Chicago, IL 2014.
  33. R. Paparodis and J. C. Jaume.  Thyroid Cancer Features in the Setting of Graves Disease.  The Endocrine Society.  Chicago, IL 2014.
  34. S. Thida, N. Chongkrairatanakul and J. C. Jaume.  The Risk of Malignancy and Outcome In Thyroid Nodules Categorized as Follicular Lesion of Undetermined Significance (FLUS).  The Endocrine Society.  Chicago, IL 2014.
  35. R. Paparodis, S. Imam, K. Todorova-Koteva, A. Staii and J.C. Jaume.  Hashimoto thyroiditis pathology and risk for thyroid cancer.  Thyroid. 2014;24:1107-14  Highlighted in Nature Endo Rev. Jun 2014
  36. S. Pandey and J. C. Jaume.  Risk of Thyroid Cancer in Prospectively Followed Euthyroid Hashimoto Thyroiditis.  The Endocrine Society.  Chicago, IL 2014.
  37. S. Imam, R. Paparodis, D. Sharma and J. C. Jaume*.  Presence of NK Cells and M1/M2 Macrophage Ratio Provides Clues for Protection Against Thyroid Cancer in Graves Disease.  The Endocrine Society.  Chicago, IL 2014. (Late Breaking Abstract and *Presidential Award Winner)
  38. S. Imam, R. Paparodis, D. Sharma and J.C. Jaume.  Lymphocytic Profiling in Cancer and Autoimmunity Provides Clues for Failure of Tumor Immunity. Endocr Relat Cancer. 2014;21:505-16
  39. S. Imam, P. S. Kumar, R. G. Mirmira and J. C. Jaume.  Eukaryotic Translation Initiation Factor 5A Inhibition Reduces Proinflamotory Cytokines and ER Stress in Beta Cell Microenvironment in a Humanized Transgenic Model of Type 1 Diabetes.  American Diabetes Association.  San Francisco, CA 2014.  (Late Breaking Abstract)
  40. D.F.Schneider, P.E. Sonderman, M.F. Jones, K.A. Ojomo, H. Chen, J.C. Jaume, D.F. Elson, S.B. Perlman, R.S. Sippel.  Failure of Radioactive Iodine in the Treatment of Hyperthyroidism.  Ann Surg Oncol. 2014;21:4174-80
  41. K-T. Hsu, X-M Yu, A. Audhya, J.C. Jaume, R. Lloyd, S. Miyamoto, T. Prolla and H. Chen.  Novel Approaches in Anaplastic Thyroid Cancer Therapy.  Oncologist. 2014;19:1148-55
  42. J. B. Hao, A. Schuna and J. C. Jaume. Extreme Insulin Resistance from Insulin Antibodies (not Insulin Receptor Antibodies) Successfully Treated with Combination Immunosuppresive Therapy.  The Endocrine Society.  San Diego, CA 2015.
  43. S. Imam, R. Paparodis and J. C. Jaume.  Does Macrophage Plasticity in Thyroid Microenvironment Decide the Fate of Thyroid cancer?  The Endocrine Society.  San Diego, CA 2015.
  44. R. Paparodis R and J. C. Jaume.  Reanalysis of the data reveal even stronger associations between Hashimoto's thyroiditis and differentiated thyroid cancer.  Thyroid. 2015;25:142
  45. J. B. Hao, S Thida, S Sirinvaravong, A Day and J. C. Jaume*.  Early Adulthood Onset Diabetes: T1DM, T2DM, Latent Autoimmune Diabetes of Adults, does it really matter?  The Endocrine Society.  Boston, MA 2016.  *Helmsley Charitable Abstract Award in T1D
  46. A. Renno, J.B. Hao, S. Imam, J.C. Jaume.  An FDA Approve Drug that Causes Type 1 Diabetes.  Is it Just Coincidence?  The Endocrine Society.  Boston, MA 2016.
  47. J. B. Hao, A. Renno, S. Imam, M. A. Alfonso-Jaume, N. Elnagar and J. C. Jaume.  Development of Type 1 Diabetes after Cancer Immunotherapy.  Endocr Pract (in press) Epub 2016.
  48. J. B. Hao, S. Imam, P. Dar, M. A. Alfonso-Jaume, N. Elnagar and J. C. Jaume.  Extreme Insulin Resistance from Insulin Antibodies (Not Insulin Receptor Antibodies) Succesfully Treated with Combination Immunosuppressive Therapy. Diabetes Care (in press) Epub 2016.

 Book Chapters

  1. J.C. Jaume.  Endocrine autoimmunity.  In Greenspan’s Basic & Clinical Endocrinology.  9th ed. Gardner DG and Shoback DM, Eds. McGraw-Hill Medical, 2011, p.27-46 (Last 5 editions).
  2. H. Chen, D.F. Schneider, H. Mazeh, J.C. Jaume, S. Lubner.  Cancer of the Endocrine System.  In Abeloff’s Clinical Oncology.  5th ed.  Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB and McKenna WG, Eds.  Churchill Livingstone Elsevier, 2013, chapter 71.

Support Our Mission

Give Now

Fund # 2402325

Last Updated: 1/29/18